Intro

This chapter analyzes recent earnings reports from major companies, emphasizing Meta's strong performance and Eli Lilly's challenges with GLP-1 drugs. It also addresses Supermicro's issues with its auditor, raising questions about its future stability.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.

Get the app